MAQS Life Science & Medtech exclusive legal partner to GPX Medical
GPX Medical AB (“GPX Medical”) has since the start in Lund 2016 revolutionized neonatal care with NEOLA®, a medical device that can offer continuous lung monitoring and real-time warnings of life-threatening complications with an advanced technology that measures changes lung volume and oxygen concentration. Shares in GPX Medical are traded on NASDAQ First North Stockholm under (“GPXMED”).
GPX Medical’s proven technology uses laser spectroscopy to continuously measure changes in lung volume and oxygen concentration in the lungs of premature babies. This is a safe and non-invasive method of monitoring the lungs of these vulnerable patients in real-time, which allows for the possible immediate detection and treatment of complications, thus improving care and reducing the risk of disability later in life.
Want to learn more about GPX Medical?
MAQS’ industry group within Life Sciences & Medtech regularly assists GPX Medical with advice on agreements regarding purchasing, sales and collaborations, as well as matters related to labour and corporate law. MAQS’ Life Science & Medtech is proud to continue as an important partner, continuing to immerse ourselves in their business during their coming growth period, and thus create the prerequisites to provide as effective, transparent and qualitative advice as possible.
Curious to read more about MAQS Life Science & Medtech?
“MAQS group within Life Science & Medtech is a very dedicated, accessible and competent partner that always provide advise based on our specific business conditions.”
Hanna Sjöström, CEO, GPX Medical